Neoral use in the renal transplant recipient (Q33920652)

30 July 2017

1 reference

title

Neoral use in the renal transplant recipient (English)

1 reference

30 July 2017

Belitsky P

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

Transplantation Proceedings

30 July 2017

published in

1 reference

30 July 2017

volume

32

1 reference

30 July 2017

issue

3A Suppl

1 reference

30 July 2017

page(s)

10S-19S

1 reference

Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Clinical pharmacokinetics of cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Neoral vs Sandimmun: interim results of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. The U. K. Neoral Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Comparison of efficacy, safety, and tolerability of Neoral vs Sandimmun in de novo renal transplant patients over 24 months' treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Renal recipients of haploidentical living donors treated with Neoral or conventional cyclosporine: a comparative follow-up of 3 years

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Neoral reduces the incidence of acute rejection after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

1 reference

7 January 2021

A microemulsion of cyclosporine without intravenous cyclosporine in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Neoral without intravenous cyclosporine in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Induction of immunosuppression by microemulsion cyclosporine in liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Use of microemulsion form cyclosporine immediately after kidney transplantation without intravenous cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997).

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Influence of drug formulation on utilization and outcomes: Neoral and monitoring by sparse sample area under the curve

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Lessons from the Neoral Global Database

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Trough cyclosporine concentration variability

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Pharmacokinetic drug interactions with cyclosporin (Part I).

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Pharmacokinetic drug interactions with cyclosporin (Part II).

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Cyclosporine microemulsion formulation (Neoral) in transplantation: pharmacokinetic/pharmacodynamic relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

Chemical modification of rapamycin: the discovery of SDZ RAD.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

FTY720: a new immunosuppressive agent with novel mechanism(s) of action

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900860-5

7 January 2021

10.1016/S0041-1345(00)00860-5

Identifiers

DOI

1 reference

30 July 2017

1 reference